مقالات پذیرفته شده در سومین کنگره بین المللی زیست پزشکی
Evaluation of Serum calprotectin levels as a biomarkerin inflammatory bowel disease
Evaluation of Serum calprotectin levels as a biomarkerin inflammatory bowel disease
Tayebeh Azramezanikopi,1Azade Amini Kadijani,2,*hadi parsain,3 Hamid Asadzadeh Aghdaei,4Shabnam Shahrokh,5
1. Student Research Committee, Babol University of Medical Sciences, Babol, Iran 2. Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti university of medical sciences, Tehran, Iran 3. Social Determinant of Health Research Center, Health Research Institute, Babol University of Medical Sciences, Babol, Iran 4. Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti university of medical sciences, Tehran, Iran 5. Basic and Molecular Epidemiology of Gastrointestinal Disorders Research Center, Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti university of medical sciences, Tehran, Iran
Introduction: Early and timely diagnosis of inflammatory bowel disease (IBD) still is a major public health problem. lack of sensitivity and imprecision of the currently available biomarkers have impaired the ability to implement potentially effective therapies in a timely manner. The present study aimed to evaluate the clinical utility of serum calprotectin in diagnosis as well as assessment of IBD.
Methods: Serum calprotectin levels were measured in 45 patients (30ulcerative colitis(UC) and 15 crohn's disease (CD) in the active phase of the disease and 30 healthy controls who refrred to the Research Institute for Gastroenterology and Liver Diseases, Shahid Beheshti university of medical sciences. blood samples from the patients and the normal controls were analyzed. the Serum calprotectin level was measured by enzyme-linked immunosorbent assay (ELISA) .
Results: Serum calprotectin levels was significantly higher in patients with IBD compared to healthy controls. The mean serum calprotectin was 5345/2±7019/1 ng/dl in IBD patients and 910 ± 272/3 ng/dl in the control group (P> 0/001).
According to ROC curves, calprotectin serum level with sensitivity and specificity was 80.9% and 79.3%, (p <0.001) can differentiate between patients and controls.
Conclusion: Findings of the study showed that SC levels vary between controls and patients and can be used as a diagnostic biomarker, Thus, it has the potential to be used as a blood-based biomarker to help in clinical management and monitoring of IBD.
Complementary studies with more homogenous and larger sample size are required to explore different aspects of these markers and resolve some inconsistencies such as their irrelevance to the disease activity.